Caraten

Caraten

carvedilol

Manufacturer:

Berlin Pharm

Distributor:

Berlin Pharm
Concise Prescribing Info
Contents
Carvedilol
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
HTN Initially 12.5 mg once daily for the 1st 2 days. Maintenance: 25 mg once daily. May increase at 2-wk intervals to a total daily dose of 50 mg once daily or in divided doses (bid). Elderly 12.5 mg once daily. Angina pectoris Initially 12.5 mg bid for the first 2 days. Maintenance: 25 mg bid. Left ventricular dysfunction following MI Initially 6.25 mg bid, may increase to 12.5 mg bid after 3-10 days & thereafter 25 mg bid. CHF Initially 3.125 mg bid for 2 wk. May increase at 2-wk intervals to 6.25 mg bid, up to max dose tolerated 25 mg bid. Patient >85 kg Max: 50 mg bid, <85 kg Max: 25 mg bid.
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Class IV uncompensated heart failure, asthma, COPD w/ bronchospastic component, severe hepatic impairment, 2nd & 3rd degree AV block, severe bradycardia, cardiogenic shock, sick sinus syndrome.
Special Precautions
Closely monitor during initiation & up-titration & dose may be reduced if worsening cardiac failure, fluid retention or bronchospasm occur. Reversible deterioration of renal function, DM, peripheral vascular disease, Raynaud's phenomenon, thyrotoxicosis, psoriasis, pheochromocytoma, Prinzmetal's variant angina, bradycardia, wearers of contact lens. May impair ability to drive or operate machinery. Pregnancy & lactation. Childn & elderly.
Adverse Reactions
Hypotension, dizziness, fatigue, hyperglycemia, diarrhea, wt gain, weakness.
Drug Interactions
Avoid concomitant use w/ dabigatran etexilate, methacholine, topotecan. May increase level/effect of α/β agonist (direct-acting), α1-blocker, α2-agonist, amifostine, antihypertensive, antipsychotic (phenothiazine), cardiac glycoside, colchicine, cyclosporin, dabigatran etexilate, digoxin, hypotensive agent, insulin, lidocaine (systemic & topical), methacholine, midodrine, P-glycoprotein substrate, rituximab, rivaroxaban, sulfonylurea, topotecan. Level/effect may be increased by acetylcholinesterase inhibitor, aminoquinoline (antimalarial), amiodarone, anilidopiperidine opioid, phenothiazine, non-dihydropyridine Ca channel blocker, cimetidine, CYP2C9 or CYP2D6 inhibitor (moderate/strong), darunavir, diazoxide, dipyridamole, disopyramide, dronedarone, herb (w/ hypotensive properties), MAOI, pentoxifylline, P-glycoprotein inhibitor, phosphodiesterase 5 inhibitor, propafenone, propoxyphene, prostacyclin analogue, quinidine, reserpine, SSRI. May decrease level/effect of β2-agonist, theophylline derivative. Level/effect may be decreased by barbiturate, herb (w/ hypertensive properties), methylphenidate, NSAIDs, peginterferon α2b, P-glycoprotein inducer, rifampicin derivative, yohimbine.
MIMS Class
ATC Classification
C07AG02 - carvedilol ; Belongs to the class of alpha and beta blocking agents. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Caraten tab 25 mg
Packing/Price
10 × 10's
Form
Caraten tab 12.5 mg
Packing/Price
10 × 10's
Form
Caraten tab 6.25 mg
Packing/Price
10 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in